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Abstract
Background
Quantifying sexually transmitted infection (STI) prevalence and incidence is important for
planning interventions and advocating for resources. The World Health Organization
(WHO) periodically estimates global and regional prevalence and incidence of four curable
STIs: chlamydia, gonorrhoea, trichomoniasis and syphilis.
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Methods and Findings
WHO’s 2012 estimates were based upon literature reviews of prevalence data from 2005
through 2012 among general populations for genitourinary infection with chlamydia, gonorrhoea, and trichomoniasis, and nationally reported data on syphilis seroprevalence among
antenatal care attendees. Data were standardized for laboratory test type, geography, age,
and high risk subpopulations, and combined using a Bayesian meta-analytic approach.
Regional incidence estimates were generated from prevalence estimates by adjusting for
average duration of infection. In 2012, among women aged 15–49 years, the estimated
global prevalence of chlamydia was 4.2% (95% uncertainty interval (UI): 3.7–4.7%), gonorrhoea 0.8% (0.6–1.0%), trichomoniasis 5.0% (4.0–6.4%), and syphilis 0.5% (0.4–0.6%);
among men, estimated chlamydia prevalence was 2.7% (2.0–3.6%), gonorrhoea 0.6% (0.4–
0.9%), trichomoniasis 0.6% (0.4–0.8%), and syphilis 0.48% (0.3–0.7%). These figures correspond to an estimated 131 million new cases of chlamydia (100–166 million), 78 million of
gonorrhoea (53–110 million), 143 million of trichomoniasis (98–202 million), and 6 million of
syphilis (4–8 million). Prevalence and incidence estimates varied by region and sex.
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Conclusions
Estimates of the global prevalence and incidence of chlamydia, gonorrhoea, trichomoniasis,
and syphilis in adult women and men remain high, with nearly one million new infections with
curable STI each day. The estimates highlight the urgent need for the public health community to ensure that well-recognized effective interventions for STI prevention, screening, diagnosis, and treatment are made more widely available. Improved estimation methods are
needed to allow use of more varied data and generation of estimates at the national level.

Introduction
Sexually transmitted infections (STIs) are among the most common acute conditions in the
world. There are over 30 infections that can be transmitted sexually. This paper focuses on four
of the most common curable STIs–Chlamydia trachomatis (chlamydia), Neisseria gonorrhoeae
(gonorrhoea), Trichomonas vaginalis (trichomoniasis), and Treponema pallidum subspecies
pallidum (syphilis). These four infections cause acute conditions such as cervicitis, urethritis,
and genital ulceration. They can also lead to severe complications and long term sequelae,
including pelvic inflammatory disease, ectopic pregnancy, infertility, chronic pelvic pain and
neurological and cardiovascular disease in adults, neonatal death, premature delivery, blindness, or severe disability in infants, and increased risk of HIV acquisition and transmission
[1,2]. STIs also frequently result in stigma, stereotyping, vulnerability and shame, and have
been associated with gender-based violence [3].
The World Health Organization (WHO) has produced estimates of the global and regional
prevalence of four curable STIs (chlamydia, gonorrhoea, trichomoniasis and syphilis) approximately every 5 years since 1995 (Table 1) [4–7]. The majority of STI public health interventions
are focused on these infections. Quantifying the prevalence and incidence of these STIs is
important for planning and estimating the impact of program interventions and advocating for
resources. In addition, these infections are curable so estimating incidence rates can provide
insight into the potential impact of STI prevention and management strategies. The epidemiological and statistical methods used have changed over time so differences in the estimates
between reports cannot be interpreted as trends over time.
WHO bases its global and regional STI estimates on literature reviews of prevalence data
among low risk or general populations and generates regional incidence estimates from the
regional prevalence values. Three contextual changes have led to a need and an opportunity to
change the WHO global estimation process for 2012. First, fewer STI prevalence studies amongst
representative samples of the general population are being conducted and published, resulting in
an increasing challenge to have sufficient number of data points to generate robust estimates.
Second, in 2008 the HIV Universal Access/Global AIDS Response Progress Reporting (GARPR)
system led by the WHO, Joint United Nations Programme on HIV and AIDS (UNAIDS), and
United Nations Children's Fund (UNICEF), began to include the prevalence of syphilis among
ANC attendees in the indicators routinely reported by countries [8]. Third, global standards for
estimation as a whole have evolved, such that it is considered important to strive for countrylevel estimates (where data allow), and to incorporate measures of uncertainty [9].
This analysis was undertaken by WHO to generate global and regional prevalence and incidence estimates for 2012 for infection with the four curable STIs (chlamydia, gonorrhoea,
trichomoniasis, and syphilis) for women and men aged 15–49 years age, based on prevalence
data collected between 2005 and 2012.
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Table 1. WHO estimates of new cases of chlamydia, gonorrhoea, trichomoniasis, and syphilis among adults for 1995, 1999, 2005, and 2008 using
various methods [4 –7].
Estimated number of new cases (millions)
1995

1999

2005

2008

Chlamydia

89

92

101

106

Gonorrhoea

62

62

88

106

Trichomoniasis

170

174

248

276

Syphilis

12

12

11

10

doi:10.1371/journal.pone.0143304.t001

Methods
Methods to generate the 2012 estimates were based on those used to generate the 2005 and
2008 estimates [6,7]. There were three major changes that were implemented that arose from
external expert consultations held by WHO in November 2013 and August 2014. First, the way
in which countries were grouped to generate regional estimates for chlamydia, gonorrhoea and
trichomoniasis was changed. In 2005 and 2008 countries were grouped into WHO regions
with two regions subdivided (Africa and the Western Pacific) [6]. For the 2012 estimates, we
defined 10 regions based on those used by the Global Burden of Disease project 2010 [10] and
on epidemiology, geography and data availability (S1 Map). Second, syphilis estimates were
based on country level data from the GARPR system; third, we used a Bayesian meta-analytic
approach to generate the estimates and uncertainty around them.

Estimating prevalence: chlamydia, gonorrhoea, and trichomoniasis
Prevalence data for chlamydia, gonorrhoea, and trichomoniasis were drawn from the data collected for the 2008 WHO estimates, PubMed literature searches (last search conducted on January 30, 2015) (S1 Text) and requests to the WHO regional STI advisors and other leading
experts in the field. In addition, members of the International Union against STIs were asked
to identify additional published or unpublished studies that met the study inclusion criteria.
Two investigators applied inclusion criteria: sample size of at least 100; specimens collected
from 2005 through 2012 (for studies in which no specimen collection date was specified the
study had to be published in 2006 or later); population could be considered representative of
the general population (study populations included pregnant women, women at delivery,
women attending family planning clinics, military recruits, or individuals selected for participation in a Demographic and Health Survey); and study used an internationally recognised
diagnostic test with adequate performance characteristics on urine, urethral, or cervicovaginal
specimens. Studies conducted among the following groups were excluded because of reasons
that are known to bias estimates of general population STI prevalence: patients seeking care for
an STI or genital symptoms, women with abnormal Papanicolaou smears, blood donors,
women attending gynaecology or sexual health clinics, remote or indigenous populations, men
who have sex with men, and commercial sex workers. Duplicate data points were removed and
if data were published in more than one paper the paper with most information was included
in the database (Fig 1). PRISMA guidance was followed for the manuscript (S2 Text).
Data from studies that met the inclusion criteria (S1 Data) were standardised to approximate the prevalence in the general population of a country by applying adjustment factors for
the laboratory diagnostic test used, study location (rural vs. urban) and the age of the study
population (S3 Text). In order to reflect the contribution of populations at higher risk of infection, the regional prevalence estimates were increased by 10% for males and females for all four
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Fig 1. PRISMA flowchart.
doi:10.1371/journal.pone.0143304.g001
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infections. The 10% figure was based on the estimate used in the 2005/08 WHO estimates [6,7]
and is a rough approximation of the contribution of these populations.
For some infections, particularly in men, there were fewer than three data points per region
for the 2005 to 2012 time period. When there were insufficient data for men, the prevalence in
men was assumed to be a proportion of the estimated prevalence in women. This proportion
was assumed to be infection-specific, but to be the same across all regions and derived from a
uniform distribution with a range of +/- 33.3% of the values used in the 2005 and 2008 estimates (Table 2).
For women there were sufficient data points to generate estimates for all regions for chlamydia but not for gonorrhoea or trichomoniasis. In the absence of data, a ratio was assumed
between the prevalence of these two infections and chlamydia. The estimated ratio was derived
from a uniform distribution within a range of +/- 33.3% (Table 2).
The estimates for the High Income North America region (United States of America and
Canada) were based on the United States national chlamydia estimates for 2012 and the gonorrhoea and trichomoniasis estimates for 2008 published by the United States Centers for Disease
Control and Prevention (CDC) [11,12]. We assumed that the prevalence of gonorrhoea and of
trichomoniasis did not change from 2008 to 2012 in the United States, that the prevalence of
each infection in Canada was the same as in the United States, and that their data (calculated
for a 15–39 year age range) could be extrapolated to the 15–49 year age range used for the
WHO estimates. The geography, age, and high risk adjustments used for other regions in the
2012 WHO estimates process were not applied (S3 Text).

Estimating prevalence: syphilis
Syphilis prevalence estimates were based on the WHO 2012 estimates of maternal and congenital syphilis [18] reported through the GARPR system for 122 of 194 (63%) countries accounting for 76% of individuals aged 15–49 years globally. A PubMed search of the peer reviewed
literature conducted in March 2014 identified data for an additional 8 (4.1%) countries missing
GARPR data. Where estimates were available from both peer-reviewed literature and GARPR,
we used the GARPR estimate because Ministry of Health officials provide the most nationally
representative data available. Such national surveillance data are typically not published in the
peer-review literature.
Syphilis prevalence estimates were calculated at country level before aggregating for regional
and global estimates. All reported data were adjusted for laboratory test to approximate the
prevalence of “probable active” infections, defined as having positive serology on both treponemal and non-treponemal tests [19]. We assumed that the prevalence of syphilis in women aged
15–49 years was the same in pregnant and non-pregnant women. In addition, we assumed that
the ratio of the prevalence of syphilis in males to females was 1 with a range of +/- 33.3%. As in
the 2005 and 2008 estimates, the regional syphilis prevalence estimates for men and women
were increased by 10% to reflect the contribution of key high risk populations.

Statistical methods used to pool data
We used a Bayesian meta-analytic approach produce pooled prevalence estimates for the 10
regional groups where there were three or more data points for a particular infection in women
or men. The beta-binomial approach for pooling over-dispersed binomial data was used as it
provides a robust estimate for the average proportion based on data from heterogeneous studies [20]. The beta-binomial model is appropriate for meta-analysis of prevalence data when the
outcome is rare, as for gonorrhoea and syphilis in some regions, and provides estimates of
uncertainty that take into account the heterogeneity observed between studies [21].
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Table 2. Ratios used to estimate prevalence when data for chlamydia, gonorrhoea, or trichomoniasis were limited.
Ratio
Male to female STI ratios—used when
fewer than three data points for a men with
a particular infection (same values used
for all regions)

Gonorrhoea to chlamydia ratio in females
—used when fewer than three gonorrhoea
data points

Trichomoniasis to chlamydia ratio in
females—used when fewer than three
trichomoniasis data points

Infection/region

Estimated
ratio

Range

Comments

Chlamydia

0.8

0.53–
1.07

Used the ratio estimated for the 2005 and
2008 [6,7]

Gonorrhoea

0.86

0.58–
1.15

Used the ratio estimated for the 2005 and
2008 [6,7]

Trichomoniasis

0.1

0.07–
0.13

Used the ratio estimated for the 2005 and
2008 [6,7]

Western, Central & Eastern
Europe, Central Asia

0.16

0.11–
0.21

Estimate based on gonorrhoea to chlamydia
ratio from published estimates for High
Income North America [11,12]

East & South East Asia

0.21

0.14–
0.28

Estimate based on the median of the ratio of
gonorrhoea to chlamydia ratio from all studies
with data on both gonorrhoea and chlamydia.
Studies where prevalence was zero for either
infection was 0 were excluded (S1 Data)

Western, Central & Eastern
Europe, Central Asia,
Australasia, High Income Asia
Paciﬁc

0.2

0.13–
0.27

Estimate based on a review of studies in
Europe presenting prevalence data for
trichomoniasis in various populations,
including STI patients [13–17]

Oceania, South Asia

1.20

0.80–
1.60

Estimate based on the median of the ratio of
trichomoniasis to chlamydia ratio from all
studies with data on both trichomoniais and
chlamydia. Studies where prevalence was
zero for either infection was 0 were excluded
(S1 Data)

doi:10.1371/journal.pone.0143304.t002

Meta-analyses were performed with a Markov Chain Monte Carlo (MCMC) algorithm
implemented with the BRrugs package [22]. For chlamydia, gonorrhoea, and trichomoniasis,
ten thousand samples were generated from the posterior distribution for the expected mean
prevalence of each regional grouping separately based on the beta-binomial model and these
were used to calculate uncertainty intervals (UI) given by the 2.5 and 97.5 percentiles. Uncertainty, calculated under this approach, reflects both the level of precision within studies (i.e.
sample size) and also additional between-study variation arising either from real differences
between study populations or differences in study methodology. Global prevalence estimates
for chlamydia, gonorrhoea and trichomoniasis were then calculated by weighting the regional
prevalence estimates according to population size. The same approach was applied for syphilis,
but country level data were used and pooled within each of the Global Burden of Disease project regions [1]. For syphilis, uncertainty was quantified based on analysis of the posterior
expected value for country level prevalence and global prevalence calculated by weighting
according to country population size. All analyses were carried out using R statistical software
[23].

Estimating incidence: chlamydia, gonorrhoea, trichomoniasis, and
syphilis
Regional incidence estimates for nine of the 10 regions were estimated from prevalence estimates. The approach was the same as in 2005 and 2008 but we also applied a range of +/33.3% around the estimated duration of infection to reflect uncertainty when calculating incidence using the equation: incidence = prevalence/average duration of infection. For the High
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Income North America region we used incidence estimates for chlamydia, gonorrhoea and
trichomoniasis based on the United States national incidence estimates [11,12].
It was assumed that the average duration of infection in each region varies according to the
average duration of infection in the absence of treatment for symptomatic and asymptomatic
individuals and the probability symptomatic and asymptomatic individuals are treated appropriately. For the 2005 and 2008 estimates countries were classified into one of three treatment
groups with a corresponding average duration of infection based on a literature review and
expert consultation [6]. A review of the literature in 2012 found insufficient data to merit
changing the assumptions for duration of infection used in 2005 and 2008 (S4 Text).
Prevalence and incidence estimates from the 10 regions were aggregated so that results
could be presented by WHO regional groupings and by World Bank income classification [24].
United Nations Population data for women and men aged 15–49 years were used to generate
numbers of prevalent and incident cases [25].

Results
The search strategy identified 63 studies with data that met the study inclusion criteria for one
or more of the three infections. An additional 16 studies were identified through other means
for a total of 79 unique studies used for analysis (S1 Data and S1 References). Extracted from
these studies were the following: 70 data points for chlamydia in women and 22 in men, 51 for
gonorrhoea in women and 13 in men, and 45 for trichomoniasis in women and two in men
(Table 3). Forest plots for the unadjusted reported data from included studies by infection,
grouped according to WHO region were produced (S1 Figs A3.1-A3.6). The data were heterogeneous, particularly for chlamydia and gonorrhoea in women in some regions.
Based on data for 2005 to 2012, the estimated pooled prevalence for chlamydia in women
globally was 4.2% (95% UI: 3.7–4.7%), with regional values ranging from 1.8% to 7.6% (S1
Figs). For gonorrhoea the global estimate was 0.8% (0.6–1.0%) and the regional values ranged
from 0.3% to 1.7%, for trichomoniasis the global estimate was 5.0% (4.0–6.4%) and the regional
values ranged from 1.0% to 11.5%, and for syphilis the global estimate was 0.5% (0.4–0.6%)
and the regional values ranged from 0.2% to 1.8% (Fig 2 and Table A in S1 Tables). Prevalence
estimates for chlamydia were highest in the Region of the Americas and Western Pacific
Table 3. Number of data points that met the study inclusion criteria for WHO 2012 estimates by infection, region, and sex. Note: A total of 79 studies
were identified, but only some provided information for all three infections. For the High Income North America region, the estimates were based on the United
States national estimates.
Regional grouping

Chlamydia

Gonorrhoea

Trichomoniasis

Women

Men

Women

Men

Women

Men

Central, Eastern & Western Sub-Saharan Africa

14

3

13

3

13

0

Southern Sub-Saharan Africa

11

0

11

0

10

0

Andean, Central, Southern & Tropical Latin America and Caribbean

10

3

5

1

5

0

High Income North America

1

1

1

1

1

1

North Africa & Middle East

6

1

4

0

5

0

Australasia & High Income Asia Paciﬁc

8

4

3

2

2

1

Western, Central & Eastern Europe and Central Asia

5

5

2

1

1

0

Oceania

8

0

8

0

1

0

South Asia

4

4

3

4

0

0

East Asia and South East Asia

3

1

1

1

7

0

Global number of studies

70

22

51

13

45

2

doi:10.1371/journal.pone.0143304.t003
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Fig 2. Estimated prevalence (and 95% UI) of chlamydia, gonorrhoea, trichomoniasis, and syphilis in women and men aged 15–49 years by WHO
region, based on 2005–2012 data.
doi:10.1371/journal.pone.0143304.g002

Region. For the other STIs, the highest estimated prevalence rates were in the African Region.
Uncertaintywas greatest for estimates of trichomoniasis prevalence.
The estimated pooled prevalence for chlamydia in men globally was 2.7% (95% UI: 2.0–
3.6%), with regional values that ranged from 1.3% to 5.2% (Fig 2 and S1 Tables). For gonorrhoea the global estimate was 0.6% (0.4–0.9%) and the regional values ranged from 0.3% to
1.0%, for trichomoniasis the global estimate was 0.6% (0.4–0.8%) and the regional values
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ranged from 0.1% to 1.3%, and for syphilis the global estimate was 0.5% (0.3–0.7%) and the
regional values ranged from 0.2% to 1.8% (Fig 2 and Table A in S1 Tables). For chlamydia and
gonorrhoea, the highest estimated prevalence rates were in the Western Pacific Region. Estimated syphilis prevalence was highest in the African Region and estimated trichomoniasis
prevalence was highest in the Region of the Americas and African Region. Uncertainty was
greatest for estimates of chlamydia prevalence.
Applying these prevalence rates to 2012 population, there were an estimated 127,361,000
prevalent cases of chlamydia, 26,819,000 prevalent cases of gonorrhoea, 100,988,000 prevalent
cases of trichomoniasis, and 17,721,000 prevalent cases of syphilis in men and women aged
15–49 years (Table 4).
The estimated prevalence of the four curable STI varied by infection and World Bank classification (Table 5). The prevalence of chlamydia among women ranged from 2.4% to 6.9%,
gonorrhoea from 0.3% to 1.2%, trichomoniasis from 1.9% to 7.8%, and syphilis from 0.2% to
1.3%. The prevalence of chlamydia among men ranged from 1.6% to 4.2%, gonorrhoea from
0.3% to 1.0%, trichomoniasis from 0.3% to 0.8%, and syphilis from 0.2% to 1.3%. A consistent
pattern was seen for syphilis in women, with increasing prevalence by decreasing income.
The global incidence rate for chlamydia was estimated to be 38 per 1,000 in women
(regional range: 15–72) and 33 per 1,000 in men (regional range: 13–64); for gonorrhoea the
rate was 19 cases per 1,000 in women (regional range: 8–37), and 24 per 1,000 in men (regional
range: 13–41), for trichomoniasis the rate was 38 cases per 1,000 in women (regional range:
8–83), and 40 per 1,000 in men (regional range: 9–94), and for syphilis 1.5 cases per 1,000 in
women (regional range: 0.9–4.4) and 1.5 per 1,000 in men (regional range: 0.9–4.4) (Fig 3 and
Table B in S1 Tables). Amongst women, regional patterns of incidence were the same as those
for prevalence. Amongst men, trichomoniasis was estimated to be the most common incident
infection.
These incidence rates translated into 131 million new cases of chlamydia, 78 million of
gonorrhoea, 143 million of trichomoniasis, and 5.6 million of syphilis in women and men aged
15–49 years in 2012 (Table 6).
Approximately 56% of these infections occurred in upper-middle income, 23% in lowermiddle income, 12% in low-income and 9% in high-income countries (Table 7).

Discussion
Summary of findings
This study suggests that, in 2012, there were about 273 million prevalent cases of the four curable STI among adults aged 15–49 years: 128 million cases of chlamydia, 27 million cases of
gonorrhoea, 101 million cases of trichomoniasis, and 18 million cases of syphilis. These figures
correspond to an estimated incidence of 131 million new chlamydia cases, 78 million new
gonorrhoea cases, 143 million new trichomoniasis cases, and 5.6 million new syphilis cases in
women and men aged 15–49 years globally. Together the four infections accounted for 357 million new infections in adults that year, or an average of nearly one million new infections each
day. Because STI co-infection is common, however, it is unclear exactly how many individuals
this represents.

Strengths and limitations
The methods used to generate the 2012 estimates of STI prevalence were based on the methods
used for the 2005 and 2008 estimates, with modifications to improve the quality of the estimates based on input from external expert consultations. In particular, the prevalence data
were pooled into 10 regions based on epidemiological similarity, geography and data

PLOS ONE | DOI:10.1371/journal.pone.0143304 December 8, 2015
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Table 4. Global and regional estimates of the number of prevalent cases (thousands) in 2012 by infection and sex (95% UI shown in parentheses).
Region
Females

African Region
Region of the Americas
Eastern Mediterranean Region

Males

Chlamydia

Gonorrhoea

Trichomoniasis

Syphilis

7,833 (5,622–11,061)

3,616 (2,355–5,510)

24,284 (18,870–30,706)

3,723 (2,981–5,302)

18,805 (16,400–21,473)

1,936 (1,205–2,785)

18,836 (10,495–32,132)

1,003 (888–1,239)

5,466 (3,821–7,892)

809 (533–1,116)

9,361 (7,049–12,562)

792 (590–1,353)

European Region

4,928 (3,628–6,514)

744 (464–1109)

2,254 (1,671–2,983)

366 (157–898)

South-East Asia Region

8,498 (6,738–10,612)

1,733 (1,109–2,492)

8,519 (5,394–13,185)

1,791 (1,580–2,021)

Western Paciﬁc Region

30,524 (24,934–36,713)

5,949 (3,834–8,450)

27,128 (16,274–43,699)

1,109 (1,046–1,249)

Global total (females)

76,054 (67,654–85,608)

14,787 (11,432–18,700)

90,381 (71,761–115,083)

8,783 (7,761–10,645)

African Region

5,328 (3,499–7,544)

1,163 (656–1,880)

2,440 (1,510–3,590)

3,726 (2,268–5,959)

Region of the Americas

4,451 (3,067–6,322)

1,584 (864–2,538)

3,193 (2,081–4,777)

992 (650–1,419)

Eastern Mediterranean Region

4,593 (2,706–7,352)

706 (411–1,089)

998 (607–1,522)

816 (465–1,498)

European Region

3,334 (1,931–5,732)

656 (345–1095)

238 (144–362)

368 (141–937)
1,856 (1,241–2,544)

South-East Asia Region

6,588 (4,344–9,203)

2,475 (1,505–3,820)

864 (457–1,458)

Western Paciﬁc Region

27,012 (18,286–37,269)

5,448 (2,898–8,898)

2,874 (1,472–5,064)

1,179 (795–1,584)

Global total (males)

51,307 (37,693–66,666)

12,033 (7,812–17,345)

10,606 (7,137–14,982)

8,938 (5,865–12,638)

doi:10.1371/journal.pone.0143304.t004

availability rather than by geography alone and greatly improved data for syphilis in women
were available at country level through the GARPR system.
The biggest challenges to estimates of this nature are the quantity, representativeness and
risk of bias of the available data. Data were included for an eight year time window (2005
through 2012), which means that changes in prevalence over time within this window will
adversely affect the accuracy of estimates for 2012, a single year. However, even with an 8 year
time window the number of data points for each infection was limited, particularly for men;
only two usable data points were identified for trichomoniasis in men. As a result, the authors
applied adjustment factors to prevalence estimates derived from available data for all four STIs
in men and for gonorrhoea and trichomoniasis in women. The current estimates are limited to
urogenital infections. Gonorrhoea and chlamydia can also be rectal and oropharyngeal infections; however, data on their prevalence is even more limited.
Where data were available, estimates of STI prevalence varied substantially. Between-study
heterogeneity could represent true variation in infection prevalence between different populations but could also result from methodological sources of bias. For example, the response rate
in chlamydia prevalence surveys in high income countries is inversely associated with the
Table 5. Prevalence by infection and World Bank classification. Note: Estimates by World Bank classification are not identical to those by geographic
region as three countries are not classified by World Bank and were therefore excluded: Cook Islands, Niue, and Nauru.
Classiﬁcation
Females

Males

Chlamydia

Gonorrhoea

Trichomoniasis

Syphilis

High-income economies

3.0%

0.3%

1.9%

0.2%

Upper-middle income economies

6.9%

1.2%

6.9%

0.3%

Lower-middle income economies

2.4%

0.6%

3.5%

0.5%

Low-income economies

2.9%

1.1%

7.8%

1.3%

Female total

4.2%

0.8%

5.0%

0.5%

High-income economies

2.4%

0.3%

0.6%

0.2%

Upper-middle income economies

4.2%

1.0%

0.7%

0.3%
0.5%

Lower-middle income economies

1.6%

0.5%

0.3%

Low-income economies

2.0%

0.5%

0.8%

1.3%

Male total

2.7%

0.6%

0.6%

0.5%

doi:10.1371/journal.pone.0143304.t005
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Fig 3. Incidence (and 95% UI) of chlamydia, gonorrhoea, trichomoniasis, and syphilis in women and men aged 15–49 years by WHO region, based
on 2005 to 2012 data.
doi:10.1371/journal.pone.0143304.g003

estimated prevalence [26]. Pooling data is not ideal under such circumstances but was necessary to generate estimates at regional and global levels. The Bayesian approach, using a betabinomial model was deemed the most appropriate method for meta-analysis, given the challenges arising from the data collection [20,21]. The over-dispersion parameter in the model
made an allowance for the between-study heterogeneity, which is reflected in the uncertainty
intervals around the mean prevalence. The estimated incidence rates were derived indirectly,
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Table 6. Global and regional estimates of the number of incident cases (in thousands) in 2012 by infection and sex (95% uncertainty interval
shown in parentheses).
Sex
Females

Region
African Region

Gonorrhoea

Trichomoniasis

Syphilis

6,616 (4,020–10,337)

7,833 (4,312–13,117)

17,529 (11,115–25,763)

920 (578–1,433)

17,775 (12,348–23,729)

4,594 (2,531–7,440)

13,776 (6,398–26,426)

471 (309–696)

Eastern Mediterranean Region

4,893 (2,923–7,716)

1,885 (1,112–2,871)

7,348 (4,702–10,909)

243 (146–481)

European Region

4,554 (2,940–6,581)

1,877 (1,060–3,048)

1,842 (1,170–2,708)

219 (92–495)

South-East Asia Region

7,168 (4,634–10,373)

3,769 (2,046–6,128)

6,151 (3,335–10,298)

435 (290–596)

Western Paciﬁc Region

27,449 (18,931–37,330)

14,138 (7,922–22,546)

21,474 (11,577–36,585)

482 (332–650)

Global total (females)

68,455 (50,649–87,648)

34,095 (23,309–47,622)

68,120 (46,632–95,620)

2,769 (2,006–3,707)

African Region

5,400 (3,098–8,510)

3,607 (1,817–6,398)

19,831 (10,462–33,096)

923 (481–1,597)

Region of the Americas

Males

Chlamydia

Region of the Americas

6,960 (4,487–10,221)

6,380 (3,114–11,214)

13,593 (5,533–27,560)

466 (253–770)

Eastern Mediterranean Region

5,634 (2,905–9,937)

2,641 (1,365–4,485)

8,241 (4,389–13,814)

253 (123–528)

European Region

4,375 (2,306–7,961)

2,809 (1,364–4,988)

1,974 (1,053–3,284)

221 (85–534)

South-East Asia Region

6,621 (3,682–10,471)

7,638 (3,982–12,962)

7,021 (3,307–12,879)

451 (243–720)

Western Paciﬁc Region

33,487 (20,202–51,084)

21,109 (10,104–37,673)

23,778 (10,978–44,515)

511 (286–804)

Global total (males)

62,477 (41,456–88,926)

44,185 (25,880–69,519)

74,438 (42,001–118,832)

2,825 (1,665–4,342)

doi:10.1371/journal.pone.0143304.t006

based on the relationship between prevalence and the duration of infection, owing to the
absence of good quality incidence data from empirical studies. Assumptions were made about
the duration of infection for women and men, levels of symptomatic and asymptomatic infection, all of which vary widely within and between countries. The 2012 duration estimates are
unchanged from the 2005 and 2008 estimates although we included a range of values to reflect
some of the uncertainty around these estimates.

Comparison with other studies
The Global Burden of Disease 2013 study included morbidity estimates of chlamydia, gonorrhoea, and trichomoniasis, and for tertiary but not primary or secondary syphilis [1]. The
Global Burden of Disease study estimated that there were 130 million new chlamydia cases, 74
million new gonorrhoea cases, and 55 million trichomoniasis cases among adults aged 15 to 49
years in 2013. The figures for chlamydia and gonorrhoea were very similar to the WHO estimates and well within the WHO uncertainty intervals. The difference in the trichomoniasis
estimates is primarily driven by the high number of new cases in men estimated by WHO (143
Table 7. Number of incident cases (‘000) in 2012 by infection and World Bank income classification. Note: Estimates by World Bank classification are
not identical to those by geographic region as three countries are not classified by World Bank and were therefore excluded: Cook Islands, Niue, and Nauru.
Sex
Females

Males

Classiﬁcation

Chlamydia

Gonorrhoea

Trichomoniasis

Syphilis

High-income economies

9,109

2,525

3,194

374

Upper-middle income economies

5,168

5,214

11,843

695

Lower-middle income economies

13,465

7,858

16,753

879

Low-income economies

40,712

18,498

36,329

822

Female total

68,455

34,095

68,120

2,769

High-income economies

11,423

3,707

2,999

389

Upper-middle income economies

4,203

2,986

13,330

689

Lower-middle income economies

11,701

10,432

18,869

905

Low-income economies

35,149

27,060

39,240

842

Male total

62,477

44,185

74,438

2,825

doi:10.1371/journal.pone.0143304.t007
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million). The high incidence of trichomoniasis in men in the WHO estimates results from the
duration of asymptomatic infection, which was assumed to be 1.5 months in men and 18
months in women. The Global Burden of Disease process did not vary presence of symptoms
or duration of infection by gender, nor did it include standardization for laboratory test performance. However, for any global estimation process, improved data on trichomoniasis among
men will be critical for improving the robustness of the estimates. The estimated prevalence of
chlamydia in high income countries is in line with estimates from a published systematic
review [26].

Interpretation of the findings
The 2012 global estimates of STI prevalence and incidence are not directly comparable with
earlier estimates and are not appropriate for doing trend analyses, owing to differences in the
methods used for each set of estimates. In 2012 the estimate for the number of new cases for
the four infections combined was 357 million. The corresponding figures for 2005 and 2008
were 448 and 498 million, respectively. The empirical data for syphilis are the most robust and
do suggest decreases over time. A recent analysis of the ANC syphilis seropositivity data on
which the current estimates were based was able to document a decrease in syphilis seropositivity among consistently reporting countries [18]. For the other infections it is not possible to say
how much of the overall decrease reflects changes in the representativeness of the data, changes
in the methods used for analysis, or true decreases in infection.
STIs are a global epidemic but there are distinct regional variations. The highest prevalence
and incidence rates for syphilis were found in the WHO African Region. Access to antenatal
syphilis screening contributes to regional differences in syphilis prevalence. In the African
region, the median reported proportion of ANC attendees tested for syphilis was 58%. The
median proportions were markedly higher in the other regions and ranged from 83 to 99%
[27]. Of note, estimated chlamydia prevalence was relatively low in the African Region and
highest in the Region of the Americas and the Western Pacific in women and in the Western
Pacific in men. The substantial unexplained heterogeneity between studies of chlamydia prevalence across and within regions deserves further detailed investigation. Both prevalence and
incidence of all four infections were lowest in the European and South-East Asian regions. Possible contributing factors are a lower risk of infection due to lower numbers of partners and
increased condom use, or better social and economic conditions including clinical STI services.
Alternatively, data from the 2005 to 2012 time period might not be representative of these
regions.
In all regions, the estimated prevalences of chlamydia in women and men, and of trichomoniasis in women were greater than gonorrhoea or syphilis prevalence. There are several potential factors contributing to these findings. Repeat infection with both trichomoniasis and
chlamydia are quite common following currently recommended single dose STI treatment regimens, often because partners are not adequately treated [28]. Additionally, most infections
with chlamydia and trichomoniasis in women are asymptomatic and remain untreated [2].
Because most men with gonorrhoea are symptomatic, syndromic management has been effective in decreasing gonorrhoea burden. The higher frequency of asymptomatic STIs in women
compared with men, resulting in a longer average duration of infection contributes to the finding that over 69% of the prevalent STI cases but only 48% of the new STI cases were among
women.
When looking at incidence by World Bank income classification, 91% of incident infections
were among individuals in low, lower-middle, and upper-middle income countries where 84%
of the population aged 15 to 49 years live. Over half (56%) of all incident infections were in
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upper-middle income countries where only 36% of the population aged 15–49 years lives. The
prevalence of chlamydia and of gonorrhoea in upper-middle income countries were strikingly
high, but it is unclear whether this was an artefact of variable data or whether this was a true
epidemiological finding due to differences in sexual risk behaviour or access to care. For syphilis in women, the infection with the most robust available data, the prevalence of infection
decreased as average country income increased. This trend also held for gonorrhoea and
trichomoniasis, apart from the data points for upper-middle income countries.

Implications of the findings
WHO and its partners are looking at options to improve the quality of future estimates and
supporting countries to generate their own national estimates. More data from studies conducted amongst women and men at low risk of infection in the general population are needed
to improve estimates of STI prevalence. For example, South Asia, South East and East Asia
Regions together had only 10 prevalence data points for chlamydia, gonorrhoea, and trichomoniasis that met the inclusion criteria, yet these three regions account for over half (54%) of the
world population aged 15–49 years. Similarly, there were only nine data points for Western,
Central, and Eastern Europe and Central Asia, all of which were for chlamydia. For many
countries, national STI reference laboratories and surveillance systems need to be strengthened.
WHO is also exploring alternative methods for generating STI prevalence and incidence estimates including approaches that use data collected from studies done in key populations, case
reports, and data from routine programmes. Robust estimates of the size of key populations
such as commercial sex workers and men who have sex with men will also be needed. Statistical
methods such as hierarchical Bayesian modelling [20] can provide the tools to combine and
explore sources of uncertainty in data from different sources.
In conclusion, the global prevalence and incidence of urogenital chlamydia, gonorrhoea,
trichomoniasis, and syphilis in adult men and women aged 15 to 49 years remain high, with
nearly one million new cases of curable STI acquired each day. The global threat of antimicrobial resistance, particularly for gonorrhoea [18], makes it essential to improve the monitoring
of changes in STI incidence. Robust estimates of STI prevalence and incidence data are important for designing, implementing and evaluating STI interventions and for advocating for funding for program and research efforts to develop improved tools such as more efficacious
therapeutics, point-of-care diagnostics, vaccines and microbicides appropriate for global use.
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